Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder | 14 | 2020 | 366 | 1.950 |
Why?
|
| Tryptophan | 7 | 2011 | 178 | 1.570 |
Why?
|
| Suicide, Attempted | 4 | 2020 | 348 | 1.260 |
Why?
|
| Serotonin | 7 | 2011 | 318 | 0.990 |
Why?
|
| Antidepressive Agents | 8 | 2020 | 228 | 0.920 |
Why?
|
| Suicidal Ideation | 5 | 2020 | 463 | 0.920 |
Why?
|
| Time Perception | 1 | 2020 | 28 | 0.690 |
Why?
|
| Depressive Disorder, Major | 4 | 2010 | 345 | 0.650 |
Why?
|
| Depression | 3 | 2020 | 1306 | 0.520 |
Why?
|
| Pain | 2 | 2017 | 786 | 0.490 |
Why?
|
| Catecholamines | 2 | 2006 | 96 | 0.450 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2004 | 43 | 0.400 |
Why?
|
| Thiophenes | 3 | 2005 | 117 | 0.340 |
Why?
|
| Neurochemistry | 1 | 2010 | 6 | 0.330 |
Why?
|
| Suicide | 1 | 2017 | 580 | 0.330 |
Why?
|
| Norepinephrine | 3 | 2006 | 210 | 0.310 |
Why?
|
| Impulsive Behavior | 2 | 2020 | 127 | 0.290 |
Why?
|
| Pain Threshold | 2 | 2019 | 79 | 0.290 |
Why?
|
| Character | 1 | 2007 | 4 | 0.280 |
Why?
|
| Frontal Lobe | 1 | 2008 | 153 | 0.280 |
Why?
|
| Inflammation | 1 | 2018 | 2737 | 0.270 |
Why?
|
| Psilocybin | 1 | 2006 | 2 | 0.270 |
Why?
|
| Temperament | 1 | 2007 | 47 | 0.270 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2006 | 176 | 0.260 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2006 | 44 | 0.260 |
Why?
|
| Middle Aged | 16 | 2020 | 31087 | 0.250 |
Why?
|
| Electroencephalography | 1 | 2008 | 399 | 0.250 |
Why?
|
| Mianserin | 2 | 2002 | 5 | 0.250 |
Why?
|
| Double-Blind Method | 5 | 2010 | 1875 | 0.240 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2005 | 34 | 0.240 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2010 | 528 | 0.240 |
Why?
|
| Citalopram | 2 | 2005 | 30 | 0.230 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 235 | 0.230 |
Why?
|
| Hallucinogens | 1 | 2006 | 102 | 0.230 |
Why?
|
| Adult | 16 | 2020 | 35495 | 0.220 |
Why?
|
| Biogenic Monoamines | 1 | 2004 | 15 | 0.220 |
Why?
|
| Brain | 2 | 2006 | 2669 | 0.200 |
Why?
|
| Young Adult | 6 | 2020 | 12388 | 0.200 |
Why?
|
| Quality Improvement | 2 | 2020 | 1095 | 0.180 |
Why?
|
| Male | 17 | 2020 | 63501 | 0.180 |
Why?
|
| Sexual Behavior | 1 | 2005 | 481 | 0.180 |
Why?
|
| Female | 18 | 2020 | 68543 | 0.170 |
Why?
|
| Analysis of Variance | 3 | 2010 | 1288 | 0.170 |
Why?
|
| Humans | 28 | 2021 | 129248 | 0.170 |
Why?
|
| beta-Endorphin | 1 | 2019 | 8 | 0.160 |
Why?
|
| Neurotensin | 1 | 2019 | 12 | 0.160 |
Why?
|
| Paroxetine | 3 | 2010 | 10 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 72 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 136 | 0.150 |
Why?
|
| Social Isolation | 1 | 2019 | 59 | 0.150 |
Why?
|
| Hospitals | 2 | 2020 | 630 | 0.150 |
Why?
|
| Infection Control | 1 | 2019 | 140 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 1019 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 103 | 0.150 |
Why?
|
| Delay Discounting | 1 | 2018 | 17 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 226 | 0.130 |
Why?
|
| Homovanillic Acid | 2 | 2010 | 10 | 0.130 |
Why?
|
| Methoxyhydroxyphenylglycol | 2 | 2010 | 14 | 0.130 |
Why?
|
| Duloxetine Hydrochloride | 3 | 2005 | 11 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2002 | 514 | 0.130 |
Why?
|
| Buprenorphine | 1 | 2020 | 162 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2021 | 602 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2020 | 252 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 436 | 0.120 |
Why?
|
| Brain Mapping | 1 | 2019 | 574 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 350 | 0.120 |
Why?
|
| Communication | 1 | 2020 | 836 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 648 | 0.110 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 14 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 909 | 0.100 |
Why?
|
| Risk Factors | 3 | 2019 | 9745 | 0.100 |
Why?
|
| Adolescent | 4 | 2019 | 20303 | 0.100 |
Why?
|
| Comorbidity | 2 | 2007 | 1544 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2019 | 506 | 0.090 |
Why?
|
| Latin America | 2 | 2021 | 87 | 0.080 |
Why?
|
| Research | 2 | 2011 | 416 | 0.080 |
Why?
|
| Neuropeptide Y | 1 | 2010 | 14 | 0.080 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2010 | 26 | 0.080 |
Why?
|
| Electrochemistry | 1 | 2010 | 80 | 0.080 |
Why?
|
| Recurrence | 2 | 2004 | 1005 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 5045 | 0.080 |
Why?
|
| Aged | 4 | 2017 | 22032 | 0.080 |
Why?
|
| Dominance, Cerebral | 1 | 2008 | 54 | 0.080 |
Why?
|
| Cyclohexanols | 2 | 2005 | 12 | 0.070 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2005 | 14 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2006 | 10199 | 0.070 |
Why?
|
| Psychometrics | 3 | 2007 | 691 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 580 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 521 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 233 | 0.070 |
Why?
|
| Personality Inventory | 1 | 2007 | 139 | 0.070 |
Why?
|
| Indoles | 1 | 2010 | 384 | 0.070 |
Why?
|
| Exploratory Behavior | 1 | 2007 | 88 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 306 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 413 | 0.060 |
Why?
|
| Affect | 1 | 2008 | 286 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2737 | 0.060 |
Why?
|
| Placebos | 1 | 2005 | 201 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 272 | 0.060 |
Why?
|
| Stereoisomerism | 1 | 2004 | 97 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1946 | 0.050 |
Why?
|
| Dopamine | 1 | 2006 | 287 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2004 | 96 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 1004 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3377 | 0.050 |
Why?
|
| Synapses | 1 | 2006 | 396 | 0.050 |
Why?
|
| Neurodegenerative Diseases | 1 | 2004 | 112 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 3079 | 0.050 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2002 | 64 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2021 | 25 | 0.050 |
Why?
|
| Neuronal Plasticity | 1 | 2004 | 279 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 1965 | 0.040 |
Why?
|
| Reaction Time | 1 | 2002 | 410 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2276 | 0.040 |
Why?
|
| Patient Care Bundles | 1 | 2019 | 20 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 154 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 4886 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 48 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2008 | 3233 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 79 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 2636 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2002 | 505 | 0.040 |
Why?
|
| Connectome | 1 | 2019 | 84 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 450 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2004 | 1715 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 389 | 0.030 |
Why?
|
| Emotions | 1 | 2002 | 538 | 0.030 |
Why?
|
| Pain Management | 1 | 2020 | 324 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 14455 | 0.030 |
Why?
|
| Public Health | 1 | 2021 | 484 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 526 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1494 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2019 | 736 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 892 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1482 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 768 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 7055 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 5736 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 6391 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3386 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 27 | 0.020 |
Why?
|
| Fluvoxamine | 1 | 2005 | 17 | 0.020 |
Why?
|
| Sertraline | 1 | 2005 | 30 | 0.020 |
Why?
|
| Syndrome | 1 | 2006 | 339 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2006 | 216 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 35307 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2003 | 69 | 0.010 |
Why?
|
| Lithium | 1 | 2002 | 37 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2002 | 89 | 0.010 |
Why?
|
| Decision Trees | 1 | 2002 | 90 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2003 | 284 | 0.010 |
Why?
|
| Morpholines | 1 | 2002 | 122 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 2008 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 393 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2002 | 216 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 737 | 0.010 |
Why?
|
| Self Efficacy | 1 | 2003 | 373 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1040 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 712 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1497 | 0.010 |
Why?
|
| Research Design | 1 | 2003 | 1043 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2002 | 736 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 757 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 7121 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2002 | 1267 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 5382 | 0.010 |
Why?
|